A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of LY3819253 in Preventing SARS-CoV-2 Infection and COVID-19 in Skilled Nursing and Assisted Living Facility Residents and Staff - a NIAID and Lilly Collaborative Study


Awarded By

Total Award Amount

  • 11246.00
  • Direct Costs

  • 7574.00
  • Sponsor Award Id

  • PO21000302
  • Contributor

  • Greer Burkholder   Principal Investigator